Rachael Fortunato, NP
Psychiatric/Mental Health · Pembroke, MANPI 1285279398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 332 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 34.3% of the total. Reporting peaked in 2023 at $1,312 and has fallen 51.9% since, to $631 in 2025. Among psychiatric/mental health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$915
- Otsuka America Pharmaceutical, Inc.$477
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$473
- Lundbeck LLC$325
- Takeda Pharmaceuticals U.S.A., Inc.$239
- plus $1K from 12 others
What the payments were for
- Food & beverage$5,21094%
- Education$3356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 121 | $1,900 |
| Johnson & Johnson | 28 | $915 |
| Otsuka America Pharmaceutical, Inc. | 24 | $477 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $473 |
| Lundbeck LLC | 48 | $325 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $239 |
| Alkermes, Inc. | 14 | $231 |
| Axsome Therapeutics, Inc. | 6 | $208 |
| Vanda Pharmaceuticals Inc. | 22 | $198 |
| Corium, LLC | 11 | $189 |
| Sunovion Pharmaceuticals Inc. | 8 | $143 |
| E.r. Squibb & Sons, L.L.C. | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $68 |
| Neuronetics, Inc. | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Sage Therapeutics, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,545 in reported general payments places this provider in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 84 | $100,396 |
| VraylarCariprazine Hcl | 42 | $83,568 |
| RexultiBrexpiprazole | 30 | $44,900 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $19,926 |
| TrintellixVortioxetine Hydrobromide | 22 | $16,554 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $4,446 |
| Ondansetron Hcl | 14 | $3,441 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 101 | $2,292 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $1,743 |
| Clonazepam | 114 | $1,232 |
| Aripiprazole | 39 | $1,156 |
| Prazosin Hcl | 60 | $1,103 |
| Clozapine | 23 | $916 |
| Mirtazapine | 52 | $900 |
| Sertraline Hcl | 39 | $804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $915 | $100,39684 claims |
| AbbVieVraylar | $1,900 | $83,56842 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $477 | $44,90030 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $239 | $20,99937 claims |
| Alkermes, Inc.Lybalvi | $231 | $19,92613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
Other psychiatric/mental health in Pembroke
- Brian BanksPembroke$47K
- Brianne LienkampMarion$121K
- Ashley BakerQuincy$54K
- Anne-Margaret BotelhoMattapoisett$46K
- Matthew PeculisWalpole$41K
- Sherrie UrenaWorcester$21K
- Irina DauphineeHanover$18K
- Schree PettigrewNew Bedford$18K
- Sherryl RosenLynn$16K
- Kevin NardoneWorcester$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.